Cargando…
Adverse events, short- and long-term outcomes of extra corporeal liver therapy in the intensive care unit: 16 years experience with MARS® in a single center
BACKGROUND: Molecular Adsorbent Recirculating System (MARS®) is a non-biological artificial liver device. The benefit risk ratio between uncertain clinical effects and potential adverse events remains difficult to assess. We sought to describe adverse events related to MARS® therapy as well as biolo...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484245/ https://www.ncbi.nlm.nih.gov/pubmed/36123713 http://dx.doi.org/10.1186/s13054-022-04165-z |
_version_ | 1784791840797491200 |
---|---|
author | Monet, Clément De Jong, Audrey Aarab, Yassir Piron, Lauranne Prades, Albert Carr, Julie Belafia, Fouad Chanques, Gérald Guiu, Boris Pageaux, Georges-Philippe Jaber, Samir |
author_facet | Monet, Clément De Jong, Audrey Aarab, Yassir Piron, Lauranne Prades, Albert Carr, Julie Belafia, Fouad Chanques, Gérald Guiu, Boris Pageaux, Georges-Philippe Jaber, Samir |
author_sort | Monet, Clément |
collection | PubMed |
description | BACKGROUND: Molecular Adsorbent Recirculating System (MARS®) is a non-biological artificial liver device. The benefit risk ratio between uncertain clinical effects and potential adverse events remains difficult to assess. We sought to describe adverse events related to MARS® therapy as well as biological and clinical effects. METHODS: All intensive care unit (ICU) admissions to whom MARS® therapy was prescribed from March 2005 to August 2021 were consecutively and prospectively included. The main endpoint was the incidence of adverse events related to MARS® therapy. Secondary endpoints were the biological and clinical effects of MARS® therapy. RESULTS: We reported 180 admissions treated with MARS® therapy. Among the 180 admissions, 56 (31.1%) were for acute-on-chronic liver failure, 32 (17.8%) for acute liver failure, 28 (15.5%) for post-surgery liver failure, 52 (28.9%) for pruritus and 12 (6.7%) for drug intoxication. At least one adverse event occurred in 95 (52.8%) admissions. Thrombocytopenia was the most frequent adverse event which was recorded in 55 admissions (30.6%). Overall, platelets count was 131 (± 95) × 10(9)/L before and 106 (± 72) × 10(9)/L after MARS® therapy (p < .001). After MARS® therapy, total bilirubin was significantly decreased in all groups (p < 0.05). Hepatic encephalopathy significantly improved in both the acute-on-chronic and in the acute liver failure group (p = 0.01). In the pruritus group, pruritus intensity score was significantly decreased after MARS® therapy (p < 0.01). CONCLUSION: In this large cohort of patients treated with MARS® therapy we report frequent adverse events. Thrombocytopenia was the most frequent adverse event. In all applications significant clinical and biological improvements were shown with MARS® therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-022-04165-z. |
format | Online Article Text |
id | pubmed-9484245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-94842452022-09-20 Adverse events, short- and long-term outcomes of extra corporeal liver therapy in the intensive care unit: 16 years experience with MARS® in a single center Monet, Clément De Jong, Audrey Aarab, Yassir Piron, Lauranne Prades, Albert Carr, Julie Belafia, Fouad Chanques, Gérald Guiu, Boris Pageaux, Georges-Philippe Jaber, Samir Crit Care Research BACKGROUND: Molecular Adsorbent Recirculating System (MARS®) is a non-biological artificial liver device. The benefit risk ratio between uncertain clinical effects and potential adverse events remains difficult to assess. We sought to describe adverse events related to MARS® therapy as well as biological and clinical effects. METHODS: All intensive care unit (ICU) admissions to whom MARS® therapy was prescribed from March 2005 to August 2021 were consecutively and prospectively included. The main endpoint was the incidence of adverse events related to MARS® therapy. Secondary endpoints were the biological and clinical effects of MARS® therapy. RESULTS: We reported 180 admissions treated with MARS® therapy. Among the 180 admissions, 56 (31.1%) were for acute-on-chronic liver failure, 32 (17.8%) for acute liver failure, 28 (15.5%) for post-surgery liver failure, 52 (28.9%) for pruritus and 12 (6.7%) for drug intoxication. At least one adverse event occurred in 95 (52.8%) admissions. Thrombocytopenia was the most frequent adverse event which was recorded in 55 admissions (30.6%). Overall, platelets count was 131 (± 95) × 10(9)/L before and 106 (± 72) × 10(9)/L after MARS® therapy (p < .001). After MARS® therapy, total bilirubin was significantly decreased in all groups (p < 0.05). Hepatic encephalopathy significantly improved in both the acute-on-chronic and in the acute liver failure group (p = 0.01). In the pruritus group, pruritus intensity score was significantly decreased after MARS® therapy (p < 0.01). CONCLUSION: In this large cohort of patients treated with MARS® therapy we report frequent adverse events. Thrombocytopenia was the most frequent adverse event. In all applications significant clinical and biological improvements were shown with MARS® therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-022-04165-z. BioMed Central 2022-09-19 /pmc/articles/PMC9484245/ /pubmed/36123713 http://dx.doi.org/10.1186/s13054-022-04165-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Monet, Clément De Jong, Audrey Aarab, Yassir Piron, Lauranne Prades, Albert Carr, Julie Belafia, Fouad Chanques, Gérald Guiu, Boris Pageaux, Georges-Philippe Jaber, Samir Adverse events, short- and long-term outcomes of extra corporeal liver therapy in the intensive care unit: 16 years experience with MARS® in a single center |
title | Adverse events, short- and long-term outcomes of extra corporeal liver therapy in the intensive care unit: 16 years experience with MARS® in a single center |
title_full | Adverse events, short- and long-term outcomes of extra corporeal liver therapy in the intensive care unit: 16 years experience with MARS® in a single center |
title_fullStr | Adverse events, short- and long-term outcomes of extra corporeal liver therapy in the intensive care unit: 16 years experience with MARS® in a single center |
title_full_unstemmed | Adverse events, short- and long-term outcomes of extra corporeal liver therapy in the intensive care unit: 16 years experience with MARS® in a single center |
title_short | Adverse events, short- and long-term outcomes of extra corporeal liver therapy in the intensive care unit: 16 years experience with MARS® in a single center |
title_sort | adverse events, short- and long-term outcomes of extra corporeal liver therapy in the intensive care unit: 16 years experience with mars® in a single center |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484245/ https://www.ncbi.nlm.nih.gov/pubmed/36123713 http://dx.doi.org/10.1186/s13054-022-04165-z |
work_keys_str_mv | AT monetclement adverseeventsshortandlongtermoutcomesofextracorporeallivertherapyintheintensivecareunit16yearsexperiencewithmarsinasinglecenter AT dejongaudrey adverseeventsshortandlongtermoutcomesofextracorporeallivertherapyintheintensivecareunit16yearsexperiencewithmarsinasinglecenter AT aarabyassir adverseeventsshortandlongtermoutcomesofextracorporeallivertherapyintheintensivecareunit16yearsexperiencewithmarsinasinglecenter AT pironlauranne adverseeventsshortandlongtermoutcomesofextracorporeallivertherapyintheintensivecareunit16yearsexperiencewithmarsinasinglecenter AT pradesalbert adverseeventsshortandlongtermoutcomesofextracorporeallivertherapyintheintensivecareunit16yearsexperiencewithmarsinasinglecenter AT carrjulie adverseeventsshortandlongtermoutcomesofextracorporeallivertherapyintheintensivecareunit16yearsexperiencewithmarsinasinglecenter AT belafiafouad adverseeventsshortandlongtermoutcomesofextracorporeallivertherapyintheintensivecareunit16yearsexperiencewithmarsinasinglecenter AT chanquesgerald adverseeventsshortandlongtermoutcomesofextracorporeallivertherapyintheintensivecareunit16yearsexperiencewithmarsinasinglecenter AT guiuboris adverseeventsshortandlongtermoutcomesofextracorporeallivertherapyintheintensivecareunit16yearsexperiencewithmarsinasinglecenter AT pageauxgeorgesphilippe adverseeventsshortandlongtermoutcomesofextracorporeallivertherapyintheintensivecareunit16yearsexperiencewithmarsinasinglecenter AT jabersamir adverseeventsshortandlongtermoutcomesofextracorporeallivertherapyintheintensivecareunit16yearsexperiencewithmarsinasinglecenter |